BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

Conditions

Fatigue in rheumatoid arthritis patients

Brief summary

The difference in least squares mean changes in the BRAF-MDQ global score from baseline to 4 weeks.

Detailed description

Changes from baseline to week 4 in the specific domains assessed by the BRAF-MDQ including Physical Fatigue, Living Fatigue, Cognitive Fatigue, and Emotional Fatigue, Changes in BRAF-NRS Severity scale, BRAF-NRS Effect scale, BRAF-NRS Coping scale from baseline to week 4., Number of (1) swollen out of 28 and (2) tender joints out of 28, (3) pain (assessed through a visual analogue scale [VAS] ranging from 0-100 where higher numbers indicates worse pain), (4) physical disability (assessed by the Health Assessment Questionnaire [HAQ]), (5) patient- and (6) doctors global assessment (assessed through a VAS ranging from 0-100 where higher numbers indicates worse assessment), and finally (7) acute phase reactants will be evaluated based on the C-reactive protein., Proportion of patients achieving a 20%, 50%, and 70% reduction in BRAF-MDQ after 4 weeks of treatment, Changes from baseline to week 4 according to the EQ-5D-5L questionnaire

Related papers

No related papers found yet.

Interventions

DRUGPlacebo (matching Tablets)

DRUGAPOVIT B1 vitamin ekstra stærk

DRUGtabletter 300 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The difference in least squares mean changes in the BRAF-MDQ global score from baseline to 4 weeks.	—

Secondary

Measure	Time frame
Changes from baseline to week 4 in the specific domains assessed by the BRAF-MDQ including Physical Fatigue, Living Fatigue, Cognitive Fatigue, and Emotional Fatigue, Changes in BRAF-NRS Severity scale, BRAF-NRS Effect scale, BRAF-NRS Coping scale from baseline to week 4., Number of (1) swollen out of 28 and (2) tender joints out of 28, (3) pain (assessed through a visual analogue scale [VAS] ranging from 0-100 where higher numbers indicates worse pain), (4) physical disability (assessed by the Health Assessment Questionnaire [HAQ]), (5) patient- and (6) doctors global assessment (assessed through a VAS ranging from 0-100 where higher numbers indicates worse assessment), and finally (7) acute phase reactants will be evaluated based on the C-reactive protein., Proportion of patients achieving a 20%, 50%, and 70% reduction in BRAF-MDQ after 4 weeks of treatment, Changes from baseline to week 4 according to the EQ-5D-5L questionnaire	—

Measure

Time frame

Changes from baseline to week 4 in the specific domains assessed by the BRAF-MDQ including Physical Fatigue, Living Fatigue, Cognitive Fatigue, and Emotional Fatigue, Changes in BRAF-NRS Severity scale, BRAF-NRS Effect scale, BRAF-NRS Coping scale from baseline to week 4., Number of (1) swollen out of 28 and (2) tender joints out of 28, (3) pain (assessed through a visual analogue scale [VAS] ranging from 0-100 where higher numbers indicates worse pain), (4) physical disability (assessed by the Health Assessment Questionnaire [HAQ]), (5) patient- and (6) doctors global assessment (assessed through a VAS ranging from 0-100 where higher numbers indicates worse assessment), and finally (7) acute phase reactants will be evaluated based on the C-reactive protein., Proportion of patients achieving a 20%, 50%, and 70% reduction in BRAF-MDQ after 4 weeks of treatment, Changes from baseline to week 4 according to the EQ-5D-5L questionnaire

—

Outcome results

None listed